دورية أكاديمية
A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis.
| العنوان: | A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis. |
|---|---|
| المؤلفون: | Daboul L; Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.; Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA., O'Donnell CM; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Amin M; Neurological Institute, Cleveland Clinic, Cleveland, OH, USA., Rodrigues P; QMENTA Cloud Platform, QMENTA Inc., Boston, MA, USA., Derbyshire J; Functional MRI Facility, NIMH, National Institutes of Health, Bethesda, MD, USA., Azevedo C; Department of Neurology, University of Southern California, Los Angeles, CA, USA., Bar-Or A; Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Caverzasi E; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.; Department of Neurology, University of California at San Francisco, San Francisco, CA, USA., Calabresi PA; Department of Neurology, Johns Hopkins University, Baltimore, MD, USA., Cree BA; Department of Neurology, University of California at San Francisco, San Francisco, CA, USA., Freeman L; Department of Neurology, Dell Medical School, The University of Texas, Austin, TX, USA., Henry RG; Department of Neurology, University of California at San Francisco, San Francisco, CA, USA., Longbrake EE; Department of Neurology, Yale University, New Haven, CT, USA., Oh J; Division of Neurology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada., Papinutto N; Department of Neurology, University of California at San Francisco, San Francisco, CA, USA., Pelletier D; Department of Neurology, University of Southern California, Los Angeles, CA, USA., Prchkovska V; QMENTA Cloud Platform, QMENTA Inc., Boston, MA, USA., Raza P; Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA., Ramos M; QMENTA Cloud Platform, QMENTA Inc., Boston, MA, USA., Samudralwar RD; Department of Neurology, University of Texas Health Science Center, Houston, TX, USA., Schindler MK; Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Sotirchos ES; Department of Neurology, Johns Hopkins University, Baltimore, MD, USA., Sicotte NL; Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Solomon AJ; Department of Neurological Sciences, Larner College of Medicine, The University of Vermont, Burlington, VT, USA., Shinohara RT; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Reich DS; Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA., Sati P; Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.; Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Ontaneda D; Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, USA. |
| المصدر: | Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2024 Jan; Vol. 30 (1), pp. 25-34. Date of Electronic Publication: 2023 Dec 13. |
| نوع المنشور: | Multicenter Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2006- : London : SAGE Publications Original Publication: Houndmills, Basingstoke, Hampshire, UK : Stockton Press, c1995- |
| مواضيع طبية MeSH: | Multiple Sclerosis*/diagnostic imaging , Multiple Sclerosis*/pathology, Adult ; Humans ; Female ; Young Adult ; Middle Aged ; Male ; Pilot Projects ; Reproducibility of Results ; Veins ; Magnetic Resonance Imaging/methods ; Brain/pathology |
| مستخلص: | Background: The central vein sign (CVS) is a proposed magnetic resonance imaging (MRI) biomarker for multiple sclerosis (MS); the optimal method for abbreviated CVS scoring is not yet established. Objective: The aim of this study was to evaluate the performance of a simplified approach to CVS assessment in a multicenter study of patients being evaluated for suspected MS. Methods: Adults referred for possible MS to 10 sites were recruited. A post-Gd 3D T2*-weighted MRI sequence (FLAIR*) was obtained in each subject. Trained raters at each site identified up to six CVS-positive lesions per FLAIR* scan. Diagnostic performance of CVS was evaluated for a diagnosis of MS which had been confirmed using the 2017 McDonald criteria at thresholds including three positive lesions (Select-3*) and six positive lesions (Select-6*). Inter-rater reliability assessments were performed. Results: Overall, 78 participants were analyzed; 37 (47%) were diagnosed with MS, and 41 (53%) were not. The mean age of participants was 45 (range: 19-64) years, and most were female ( n = 55, 71%). The area under the receiver operating characteristic curve (AUROC) for the simplified counting method was 0.83 (95% CI: 0.73-0.93). Select-3* and Select-6* had sensitivity of 81% and 65% and specificity of 68% and 98%, respectively. Inter-rater agreement was 78% for Select-3* and 83% for Select-6*. Conclusion: A simplified method for CVS assessment in patients referred for suspected MS demonstrated good diagnostic performance and inter-rater agreement. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: L.D., C.M.O.D, M.A., J.D., E.C., P.Ra., and M.K.S. have declared no conflicts of interest. P.Ro. employed by and holds stocks in QMENTA. C.A. received consulting fees for scientific advisory boards for Genentech, EMD Serono, Alexion Pharmaceuticals, and Sanofi Genzyme. A.B.O. has received personal fees for advisory board participation and consulting from Abata, Accure, Atara Biotherapeutics, Biogen, BMS/Celgene/Receptos, GlaxoSmithKline, Gossamer, Horizon Therapeutics, Immunic, Janssen/Actelion, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech, Sangamo, Sanofi Genzyme, Viracta; and grant support to the University of Pennsylvania from Biogen Idec, Roche/Genentech, Merck/EMD Serono, and Novartis. P.A.C. is a PI on grants to JHU from Biogen and Annexon and served on scientific advisory boards for Disarm Therapeutics and Biogen. B.A.C.C. received compensation for consulting from Alexion, Atara, Biogen, EMD Serono, Novartis, Sanofi, and TG Therapeutics. L.F. received fees for consultancy and advisory board participation from Genentech, Novartis, Celgene/Bristol Myers Squibb, EMD Serono, and TG Therapeutics; received fees for educational activities from Medscape, LLC, and the MS Association of America; program sponsorship to UT from EMD Serono; and grant support to UT from NIH/NINDS, PCORI, Genentech, and EMD Serono. R.G.H. received research support from Roche, Genentech, Atara, and MedDay and consulting for Novartis, Sanofi/Genzyme, Roche/Genentech, QIA, and Neurona. E.E.L. received research support from Genentech, Biogen and consulting for Genentech, Janssen, TG Therapeutics, NGM Bio, Bristol Myers Squibb, and EMD Serono. J.O. received research support from Biogen Idec, Roche, and EMD Serono; consulting compensation from EMD Serono, Sanofi/Genzyme, Biogen Idec, Roche, Celgene, and Novartis. N.P. received research support from the Race to Erase MS Foundation. D.P. received consulting compensation from EMD Serono, Sanofi Genzyme, Roche, and Novartis. V.P. employed by and holds stocks in QMENTA. M.R. employed by and holds stock options in QMENTA. R.D.S. received fees for advisory board participation (Biogen, EMD Serono, Sanofi Genzyme) and consulting (EMD Serono, Biogen). E.S. received fees for scientific advisory boards and consulting for Alexion, Viela Bio, Horizon Therapeutics, Genentech, and Ad Scientiam; speaking honoraria from Alexion, Viela Bio, and Biogen. N.L.S. received research support from the National Institutes of Health, National Multiple Sclerosis Society, Patient-Centered Outcomes Research Institute, Race to Erase MS Foundation, and Biogen Idec. A.J.S. received fees for consulting: Greenwich Biosciences, Horizon Therapeutics, Kiniksa Pharmaceuticals, Octave Bioscience, TG Therapeutics; non-promotional speaking: EMD Serono; research funding: Bristol Myers Squibb; contracted research: Sanofi, Novartis, Actelion, Genentech/Roche. R.T.S. supported NIH R01NS112274, R01MH112847, and R01MH123550 and received consulting income from Octave Bioscience. D.S.R. supported by the Intramural Research Program of NINDS; received additional research support from Vertex Pharmaceuticals, Sanofi Genzyme, and Abata Therapeutics. P.S. received research support from the National Institutes of Health and the National Multiple Sclerosis Society. D.O. received research support from the National Institutes of Health, National Multiple Sclerosis Society, Patient-Centered Outcomes Research Institute, Race to Erase MS Foundation, Genentech, Genzyme, and Novartis; consulting fees from Biogen Idec, Genentech/Roche, Genzyme, Novartis, and Merck. |
| References: | Neuroimage Clin. 2021;32:102834. (PMID: 34592690) J Neurol. 2018 Nov;265(11):2684-2687. (PMID: 30196327) Mult Scler. 2018 May;24(6):750-757. (PMID: 28820013) Lancet Neurol. 2018 Feb;17(2):162-173. (PMID: 29275977) Eur Radiol. 2014 Apr;24(4):841-9. (PMID: 24317461) Sci Rep. 2023 Feb 8;13(1):2249. (PMID: 36754987) Lancet Neurol. 2023 Aug;22(8):750-768. (PMID: 37479377) Ann Neurol. 2018 Feb;83(2):283-294. (PMID: 29328521) Mult Scler Relat Disord. 2018 Oct;25:99-103. (PMID: 30059896) Mult Scler. 2020 Apr;26(4):433-441. (PMID: 31668125) Clin Neurol Neurosurg. 2020 Dec;199:106278. (PMID: 33069931) Mult Scler. 2016 Sep;22(10):1289-96. (PMID: 26658816) Sci Rep. 2019 Dec 3;9(1):18188. (PMID: 31796822) Diagnostics (Basel). 2020 Nov 29;10(12):. (PMID: 33260401) Mult Scler. 2020 Apr;26(4):421-432. (PMID: 31536435) Mult Scler. 2017 Aug;23(9):1233-1240. (PMID: 27754943) Nat Rev Neurol. 2016 Dec;12(12):714-722. (PMID: 27834394) NMR Biomed. 2020 May;33(5):e4283. (PMID: 32125737) Neurology. 2021 Oct 26;97(17):e1641-e1652. (PMID: 34521693) Neurology. 2016 Sep 27;87(13):1393-9. (PMID: 27581217) Lancet Neurol. 2016 Mar;15(3):292-303. (PMID: 26822746) AJNR Am J Neuroradiol. 2018 Oct;39(10):1806-1813. (PMID: 30213803) Neurology. 2017 Oct 17;89(16):1668-1675. (PMID: 28931645) Radiology. 2012 Dec;265(3):926-32. (PMID: 23074257) Mult Scler. 2019 Oct;25(11):1488-1495. (PMID: 30043667) J Neuroimaging. 2017 Jan;27(1):114-121. (PMID: 27300318) JAMA Neurol. 2018 Nov 1;75(11):1392-1398. (PMID: 30083703) Mult Scler Relat Disord. 2022 Jan;57:103361. (PMID: 35158432) JAMA Neurol. 2019 Dec 1;76(12):1446-1456. (PMID: 31424490) Mult Scler Relat Disord. 2019 May;30:51-56. (PMID: 30738280) Neurology. 2011 Feb 8;76(6):534-9. (PMID: 21300968) AJNR Am J Neuroradiol. 2019 May;40(5):776-783. (PMID: 31000526) |
| معلومات مُعتمدة: | R01 MH123550 United States MH NIMH NIH HHS; ZIA NS003119 United States ImNIH Intramural NIH HHS; R35 NS111644 United States NS NINDS NIH HHS; R01 NS060910 United States NS NINDS NIH HHS; R01 NS112274 United States NS NINDS NIH HHS; R01 MH112847 United States MH NIMH NIH HHS |
| فهرسة مساهمة: | Keywords: Central vein sign; FLAIR*; MRI; biomarkers; multiple sclerosis |
| تواريخ الأحداث: | Date Created: 20231213 Date Completed: 20240111 Latest Revision: 20240426 |
| رمز التحديث: | 20240426 |
| مُعرف محوري في PubMed: | PMC11037932 |
| DOI: | 10.1177/13524585231214360 |
| PMID: | 38088067 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1477-0970 |
|---|---|
| DOI: | 10.1177/13524585231214360 |